AbCellera Biologics Inc. (ABCL) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
ABCL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ABCL Revenue Analysis (2018–2025)
As of March 2, 2026, AbCellera Biologics Inc. (ABCL) generated trailing twelve-month (TTM) revenue of $75.1 million, reflecting explosive growth of +788.2% year-over-year. The most recent quarter (Q4 2025) recorded $44.9 million in revenue, up 400.9% sequentially.
Looking at the longer-term picture, ABCL's 5-year compound annual growth rate (CAGR) stands at -20.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $485.4 million in 2022.
Revenue diversification analysis shows ABCL's business is primarily driven by License (62%), Research Fees (36%), and Milestone Payments (1%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), ABCL has outperformed the peer group in terms of revenue growth. Compare ABCL vs REGN →
Peer Comparison
Compare ABCL's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ABCLCurrent | $75M | +788.2% | -20.3% | -289.0% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $75.1M | +160.6% | $0 | - | $-217,103,000 | -289.0% |
| 2024 | $28.8M | -24.2% | $28.8M | 100.0% | $-314,766,000 | -1091.7% |
| 2023 | $38.0M | -92.2% | $38.0M | 100.0% | $-237,207,000 | -623.8% |
| 2022 | $485.4M | +29.4% | $419.0M | 86.3% | $216.5M | 44.6% |
| 2021 | $375.2M | +60.9% | $329.7M | 87.9% | $204.4M | 54.5% |
| 2020 | $233.2M | +1907.9% | $206.0M | 88.4% | $156.0M | 66.9% |
| 2019 | $11.6M | +31.5% | $11.6M | 100.0% | $-4,117,000 | -35.5% |
| 2018 | $8.8M | - | $3.0M | 34.3% | $-753,000 | -8.5% |
See ABCL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABCL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABCL vs AGIO
See how ABCL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABCL's revenue growth accelerating or slowing?
ABCL revenue is accelerating at +788.2% year-over-year, exceeding the 5-year CAGR of -20.3%. TTM revenue reached $75M. Growth momentum has increased versus prior periods.
What is ABCL's long-term revenue growth rate?
AbCellera Biologics Inc.'s 5-year revenue CAGR of -20.3% reflects the sustained expansion pattern. Current YoY growth of +788.2% is above this long-term average.
How is ABCL's revenue distributed by segment?
ABCL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.